• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.

作者信息

Tu Shi-Ming, Lin Sue-Hwa, Logothetis Christopher

出版信息

J Natl Cancer Inst. 2003 Aug 6;95(15):1174-5; author reply 1175. doi: 10.1093/jnci/djg020.

DOI:10.1093/jnci/djg020
PMID:12902452
Abstract
摘要

相似文献

1
Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.回复：唑来膦酸治疗激素难治性转移性前列腺癌患者的随机、安慰剂对照试验
J Natl Cancer Inst. 2003 Aug 6;95(15):1174-5; author reply 1175. doi: 10.1093/jnci/djg020.
2
Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.回复：唑来膦酸治疗激素难治性转移性前列腺癌患者的随机、安慰剂对照试验
J Natl Cancer Inst. 2003 Feb 19;95(4):332; author reply 333-4. doi: 10.1093/jnci/95.4.332.
3
Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.回复：唑来膦酸治疗激素难治性转移性前列腺癌患者的随机安慰剂对照试验
J Natl Cancer Inst. 2003 Feb 19;95(4):332; author reply 333-4. doi: 10.1093/jnci/95.4.332-a.
4
Re: A Randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.回复：唑来膦酸治疗激素难治性转移性前列腺癌患者的一项随机、安慰剂对照试验
J Natl Cancer Inst. 2004 Aug 4;96(15):1183; author reply 1183-1184. doi: 10.1093/jnci/djh234.
5
Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.回复：唑来膦酸用于激素难治性转移性前列腺癌患者的随机安慰剂对照试验
J Natl Cancer Inst. 2003 Feb 19;95(4):332-3; author reply 333-4. doi: 10.1093/jnci/95.4.332-b.
6
Re: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer.回复：唑来膦酸预防转移性激素难治性前列腺癌患者骨骼并发症的长期疗效
J Natl Cancer Inst. 2005 Feb 2;97(3):235-6. doi: 10.1093/jnci/dji037.
7
A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.唑来膦酸治疗激素难治性转移性前列腺癌患者的一项随机、安慰剂对照试验。
J Natl Cancer Inst. 2002 Oct 2;94(19):1458-68. doi: 10.1093/jnci/94.19.1458.
8
Bisphosphonates in prostate cancer: where are we and where should we go?
J Natl Cancer Inst. 2003 Sep 3;95(17):1262-3. doi: 10.1093/jnci/djg062.
9
Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer.唑来膦酸预防转移性激素难治性前列腺癌患者骨骼并发症的长期疗效。
J Natl Cancer Inst. 2004 Jun 2;96(11):879-82. doi: 10.1093/jnci/djh141.
10
Re: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer.
J Natl Cancer Inst. 2004 Oct 6;96(19):1480; author reply 1480-1. doi: 10.1093/jnci/djh294.